Trials / Completed
CompletedNCT01344707
Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS)
Open Label, Dose Escalation Study of 4SC-202 in Patients With Advanced Hematologic Malignancies: First-In-Man Study of a Newly Developed, Oral Histone Deacetylase Inhibitor
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- 4SC AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the Maximum Tolerated Dose, Dose Limiting Toxicities and optimal dosing schedule of 4SC-202 investigating its safety, tolerability and pharmacokinetics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 4SC-202 | oral administration dose escalation twice daily (bid)or three times a day (tid) continuous dosing for 21 days per cycle |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2015-03-01
- Completion
- 2015-03-01
- First posted
- 2011-04-29
- Last updated
- 2015-04-01
Locations
3 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01344707. Inclusion in this directory is not an endorsement.